human itgb6 antibody  (R&D Systems)

Journal: bioRxiv

Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

doi: 10.1101/2024.04.18.590156

Figure Lengend Snippet: (A) Human Protein Atlas analysis of RNA expression of ITGB6 across various cancer types. Normalized RNA expression levels are given in fragments per kilobase million (FPKM). Data are acquired from TCGA. Graphs show the mean and SD. ( B) Differential gene expression analysis of ITGB6 across tumor and normal tissue. Data are obtained from a standardized concatenated data set from GEO, GTex, TCGA, and TARGET databases. RNA-seq tumor and normal tissue samples are obtained from the same patients and from adjacent sites. Graphs were generated using the TNMplot tool and were normalized using DESeq2. Fold-change (FC) of medians and Mann-Whitney test p-values are shown.

Article Snippet: The human cell lines HCT116WT, Capan-2, FaDu, and CAL27 were screened via flow cytometry using an APC-conjugated human ITGB6 antibody (R&D Systems, # FAB4155A).

Techniques: RNA Expression, Gene Expression, RNA Sequencing, Generated, MANN-WHITNEY

Journal: bioRxiv

Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

doi: 10.1101/2024.04.18.590156

Figure Lengend Snippet: (A) ITGB6 RNA of selected human cancer cell lines from the Human Protein Atlas. (B) Flow cytometry analysis of the percentage of cancer cells that are ITGB6+ based on unstained controls. (C) Western blot validation of the CRISPR knockout of ITGB6 in FaDu and CAL27 cells. (D) Colony formation assay of CRISPR control (CTRL) cells and ITGB6 knockouts (KO-1) for FaDu and CAL27 cells. (E) Quantification of colony formation assay. Statistical analysis was performed using an unpaired t-test. Randomly chosen fields of view from the co-culture of FaDu (F) or CAL-27 (G) HNSCC cells (green) and TALL-104 T-cells (blue) (n = 10). Cells were pretreated for 8 hrs with latent TGFβ. Quantification of cancer cell counts for FaDu (H) and CAL27 (J). Quantification of the percentage of cancer cells that are dead for FaDu (I) and CAL27 (K). One-way ANOVA: p < 0.0001 (****), p < 0.002 (**).

Article Snippet: The human cell lines HCT116WT, Capan-2, FaDu, and CAL27 were screened via flow cytometry using an APC-conjugated human ITGB6 antibody (R&D Systems, # FAB4155A).

Techniques: Flow Cytometry, Western Blot, Biomarker Discovery, CRISPR, Knock-Out, Colony Assay, Control, Co-Culture Assay

Journal: bioRxiv

Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

doi: 10.1101/2024.04.18.590156

Figure Lengend Snippet: (A) Flow cytometry analysis of the percentage of mouse cancer cells that are ITGB6+ based on unstained controls. (B) Western blot validation of CRISPR knockdown of ITGB6 in MOC1 and KPCY cells. (C) Colony formation assay of CRISPR control (CTRL) cells and ITGB6-knockout (KO-1, KO-2) cells for MOC1 and KPCY cells. (D) Quantification of colony formation assay. Statistical analysis was performed using one-way ANOVA: p < 0.05 (*). (E) Experimental timeline for C57BL/6 mice injected with syngeneic tumor cells. Tumor volume of mice starting upon tumor formation at day 5 for MOC1 (F) and KPCY (H) cohorts (n = 10). Mass of MOC1 (G) and KPCY (I) tumors harvested at day 25. Statistical comparison between CTRL and KO-1 cohorts was performed using an unpaired t-test: p < 0.001 (***), p < 0.05 (*).

Article Snippet: The human cell lines HCT116WT, Capan-2, FaDu, and CAL27 were screened via flow cytometry using an APC-conjugated human ITGB6 antibody (R&D Systems, # FAB4155A).

Techniques: Flow Cytometry, Western Blot, Biomarker Discovery, CRISPR, Knockdown, Colony Assay, Control, Knock-Out, Injection, Comparison

Journal: bioRxiv

Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

doi: 10.1101/2024.04.18.590156

Figure Lengend Snippet: Curves show the overall survival of patients with various cancer types stratified based on ITGB6 expression. Patients with high ITGB6 have expression levels above +0.25 σ of the mean and ITGB6 low patients have expression below -0.25 σ. The graphs were generated using TCGA data through the cBioPortal. Statistical analysis of Kaplan-Meier curves and corresponding hazard ratios (HR) was performed using the Log-rank test.

Article Snippet: The human cell lines HCT116WT, Capan-2, FaDu, and CAL27 were screened via flow cytometry using an APC-conjugated human ITGB6 antibody (R&D Systems, # FAB4155A).

Techniques: Expressing, Generated

Journal: bioRxiv

Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

doi: 10.1101/2024.04.18.590156

Figure Lengend Snippet: (A) Pan-cancer analysis of ITGB6 RNA expression level normalized using DESeq2 of patients who are either responsive or unresponsive to immune checkpoint blockade. RNA data are extracted from a TCGA data set of multiple cancer types of patients who underwent immune checkpoint blockade therapy. Graphs were generated using the ROCplot tool and the results of an unpaired t-test are shown. (B) Kaplan-Meier curves of overall survival of patients undergoing immune checkpoint blockade therapy stratified into low and high ITGB6 expression about the mean. Statistical analysis was performed using the Log-rank test.

Article Snippet: The human cell lines HCT116WT, Capan-2, FaDu, and CAL27 were screened via flow cytometry using an APC-conjugated human ITGB6 antibody (R&D Systems, # FAB4155A).

Techniques: RNA Expression, Generated, Expressing